Pipeline new from Jazz, Wize Pharma, Stealth Biotherapeutics, Ocular Therapeutix and SCYNEXIS

May 7, 2018

Company Drug/Device Medical Condition Status
Ocular Therapeutix OTX-TIC (travoprost intracameral implant) glaucoma and ocular hypertension Phase I trial initiated
Galapagos NV and MorphoSys AG MOR106 moderate-to-severe atopic dermatitis (AD) Phase II trial initiated evaluating 180 subjects
ThromboGenics NV THR-317 administered in combination with ranibizumab (Lucentis, Novartis) Diabetic Macular Edema (DME) Phase II trial initiated enrolling 70 subjects
Wize Pharma, Inc. LO2A Symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome Phase IV trial initiated enrolling 60 subjects in the Israel
Immusoft Corporation Immune System Programming MPS I (Mucopolysaccharidosis type I) Orphan Drug Designation granted by the FDA
Stealth Biotherapeutics elamipretide Leber’s hereditary optic neuropathy (LHON) Orphan Drug Designation granted by the FDA
Conavi TM Medical Inc. Novasight Hybrid System simultaneous imaging of coronary arteries with both intravascular ultrasound (VUS) and Optical Coherence Tomography (OCT) 510(k) clearance granted by the FDA
Jazz Pharmaceuticals Xyrem (sodium oxybate) oral solution cataplexy and Excessive Daytime Sleepiness (EDS) in pediatric narcolepsy patients sNDA filed with the FDA
Acceleron Pharma Inc. ACE-083 Facioscapulohumeral muscular dystrophy (FSHD) treatment Fast Track Designation granted by the FDA
SCYNEXIS, Inc. Oral SCY-078 vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC Fast Track Designation and Qualified Infectious Disease Product (QIDP) granted by the FDA